Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending August 04, 2008. The document serves as a notification of transactions involving directors and persons discharging managerial responsibility, specifically regarding the US Retirement Savings Plan.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. The only financial figure disclosed is the price of $46.56 per ADR used for a notional re-valuation within the US Retirement Savings Plan.
Material Changes
Following a re-valuation of the cash element of the notional investment held in GSK Ordinary Share ADRs, the Plan Administrators notified the company of an increase in the notional allocation of Ordinary Share ADRs on July 31, 2008. This transaction was reported in accordance with Disclosure and Transparency Rule 3.1.4R(1)(a).
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, risk factors, or contingencies. It is strictly a regulatory disclosure of specific director-related transactions.
Important Facts for Investors
- The filing discloses an increase in notional ADR allocations for seven individuals, including Dr. M M Slaoui, Mrs. C Bruck Slaoui, Mr. C Viehbacher, Mr. E J Gray, Mr. W C Louv, Dr. D Pulman, and Mr. S M Werner.
- The transaction price for the notional allocation was $46.56 per ADR.
- The notification date was August 4, 2008, relating to activity on July 31, 2008.
- No financial performance data or strategic updates are included in this specific report.